Skip to main content

Table 1 Spearman's correlations on changes in the 2 clinical trials

From: Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)

  Methotrexate trial Meloxicam trial
  JADAS-71 JADAS-27 JADAS-10 JADAS-71 JADAS-27 JADAS-10
CHAQ 0.46 0.50 0.51 0.44 0.43 0.45
DAS28 0.78 0.80 0.79 0.74 0.74 0.70
CDAI 0.88 0.86 0.72 0.87 0.86 0.75
  1. The JADAS-10 revealed the best discriminative validity, followed by the JADAS-27 and the JADAS-71.